Vitamin B12-dependent taurine synthesis regulates growth and bone mass

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 2988-3002

  Roman Garcia, Pablo ^a   Quiros Gonzalez, Isabel ^a   Mottram, Lynda ^a   Lieben, Liesbet ^a   Sharan, Kunal ^a   Wangwiwatsin, Arporn ^a   Tubio, Jose ^a   Lewis, Kirsty ^a   Wilkinson, Debbie ^b   Santhanam, Balaji ^a,c   Sarper, Nazan ^d   Clare, Simon ^a   Vassiliou, George S ^a   Velagapudi, Vidya R ^e   Dougan, Gordon ^a   Yadav, Vijay K ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^d KOCAELI UNIVERSITY   (Turkey)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYANOCOBALAMIN; GROWTH HORMONE; SOMATOMEDIN C; TAURINE; INSULIN LIKE GROWTH FACTOR 1, MOUSE; INSULIN-LIKE GROWTH FACTOR-1, MOUSE; INTRINSIC FACTOR; STAT5 PROTEIN;

AMINO ACID SYNTHESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE GROWTH; BONE MASS; CONTROLLED STUDY; CYANOCOBALAMIN DEFICIENCY; DISEASE SEVERITY; FEMALE; GENETIC MODEL; GENOTYPE; GROWTH REGULATION; GROWTH RETARDATION; HORMONE SYNTHESIS; HUMAN; HUMAN CELL; LIVER METABOLISM; MALE; METABOLOMICS; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOPOROSIS; PHENOTYPE; PRIORITY JOURNAL; PROGENY; WEANING; ANIMAL; BIOSYNTHESIS; BONE DENSITY; BONE DEVELOPMENT; C57BL MOUSE; GENETICS; GROWTH; GROWTH DISORDER; KNOCKOUT MOUSE; LIVER; METABOLISM; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATION; PRENATAL EXPOSURE;

ANIMALS; BONE DENSITY; BONE DEVELOPMENT; FEMALE; GROWTH; GROWTH DISORDERS; GROWTH HORMONE; INSULIN-LIKE GROWTH FACTOR I; INTRINSIC FACTOR; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPOROSIS; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; STAT5 TRANSCRIPTION FACTOR; TAURINE; VITAMIN B 12; VITAMIN B 12 DEFICIENCY;

EID: 84903762399     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI72606     Document Type: Article

References (45)

1. Dloniak SM, French JA, Holekamp KE. Rank-related maternal effects of androgens on behaviour in wild spotted hyaenas. Nature. 2006;440(7088):1190- 1193.
2. Oury F, et al. Maternal and offspring pools of osteocalcin influence brain development and functions. Cell. 2013;155(1):228-241.
3. Weaver IC, et al. Epigenetic programming by maternal behavior. Nat Neurosci. 2004;7(8):847-854.
4. Karsenty G, Kronenberg HM, Settembre C. Genetic control of bone formation. Annu Rev Cell Dev Biol. 2009;25:629-648.
5. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet. 2003;4(8):638-649.
6. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000;21(2):115-137.
7. Zaidi M. Skeletal remodeling in health and disease. Nat Med. 2007;13(7):791-801.
8. Khosla S. Pathogenesis of age-related bone loss in humans. J Gerontol A Biol Sci Med Sci. 2013; 68(10):1226-1235.
9. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature. 2003; 423(6937):349-355.
10. Goerss JB, Kim CH, Atkinson EJ, Eastell R, O?Fallon WM, Melton LJ. Risk of fractures in patients with pernicious anemia. J Bone Miner Res. 1992;7(5):573-579.
11. Dhonukshe-Rutten RA, van Dusseldorp M, Schneede J, de Groot LC, van Staveren WA. Low bone mineral density and bone mineral content are associated with low cobalamin status in adolescents. Eur J Nutr. 2005;44(6):341-347.
12. Tucker KL, et al. Low plasma vitamin B12 is associated with lower BMD: the Framingham Osteoporosis Study. J Bone Miner Res. 2005;20(1):152-158.
13. Morris MS, Jacques PF, Selhub J. Relation between homocysteine and B-vitamin status indicators and bone mineral density in older Americans. Bone. 2005;37(2):234-242.
14. Carmel R, Lau KH, Baylink DJ, Saxena S, Singer FR. Cobalamin and osteoblast-specific proteins. N Engl J Med. 1988;319(2):70-75.
15. Muthayya S, et al. Low maternal vitamin B12 status is associated with intrauterine growth retardation in urban South Indians. Eur J Clin Nutr. 2006; 60(6):791-801.
16. Merriman NA, Putt ME, Metz DC, Yang YX. Hip fracture risk in patients with a diagnosis of pernicious anemia. Gastroenterology. 2010;138(4):1330-1337.
17. Nielsen MJ, Rasmussen MR, Andersen CB, Nexo E, Moestrup SK. Vitamin B12 transport from food to the body?s cells-a sophisticated, multistep pathway. Nat Rev Gastroenterol Hepatol. 2012;9(6):345-354.
18. Kalhan SC, Marczewski SE. Methionine, homocysteine, one carbon metabolism and fetal growth. Rev Endocr Metab Disord. 2012;13(2):109-119.
19. Lazar MA, Birnbaum MJ. Physiology. De-meaning of metabolism. Science. 2012;336(6089):1651-1652.
20. Stratikopoulos E, Szabolcs M, Dragatsis I, Klinakis A, Efstratiadis A. The hormonal action of IGF1 in postnatal mouse growth. Proc Natl Acad Sci U S A. 2008;105(49):19378-19383.
21. Long F, Joeng KS, Xuan S, Efstratiadis A, McMahon AP. Independent regulation of skeletal growth by Ihh and IGF signaling. Dev Biol. 2006;298(1):327-333.
22. Bex M, Bouillon R. Growth hormone and bone health. Horm Res. 2003;60(suppl 3):80-86.
23. DiGirolamo DJ, et al. Mode of growth hormone action in osteoblasts. J Biol Chem. 2007; 282(43):31666-31674.
24. Carroll PV, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 1998;83(2):382-395.
25. Vijayakumar A, Yakar S, Leroith D. The intricate role of growth hormone in metabolism. Front Endocrinol (Lausanne). 2011;2:32.
26. Lu M, et al. Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1. Nat Med. 2012;18(3):388-395.
27. Xian L, et al. Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med. 2012;18(7):1095-1101.
28. Sturman JA. Taurine in development. Physiol Rev. 1993;73(1):119-147.
29. Verner A, Craig S, McGuire W. Effect of taurine supplementation on growth and development in preterm or low birth weight infants. Cochrane Database Syst Rev. 2007;(4):CD006072.
30. Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene. 2000;19(21):2585-2597.
31. Wan M, et al. Postprandial hepatic lipid metabolism requires signaling through Akt2 independent of the transcription factors FoxA2, FoxO1, and SREBP1c. Cell Metab. 2011;14(4):516-527.
32. Holloway MG, Cui Y, Laz EV, Hosui A, Hennighausen L, Waxman DJ. Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology. 2007; 148(5):1977-1986.
33. Fu Q, Yu X, Callaway CW, Lane RH, McKnight RA. Epigenetics: intrauterine growth retardation (IUGR) modifies the histone code along the rat hepatic IGF-1 gene. FASEB J. 2009;23(8):2438-2449.
34. Jing X, et al. Crosstalk of humoral and cell-cell contact-mediated signals in postnatal body growth. Cell Rep. 2012;2(3):652-665.
35. Masternak MM, Panici JA, Wang F, Wang Z, Spong A. The effects of growth hormone (GH) treatment on GH and insulin/IGF-1 signaling in long-lived Ames dwarf mice. J Gerontol A Biol Sci Med Sci. 2010; 65(1):24-30.
36. Sesmilo G, et al. Effects of growth hormone (GH) administration on homocyst(e)ine levels in men with GH deficiency: a randomized controlled trial. J Clin Endocrinol Metab. 2001;86(4):1518-1524.
37. Pons L, et al. Anchoring secreted proteins in endoplasmic reticulum by plant oleosin: the example of vitamin B12 cellular sequestration by transcobalamin. PLoS One. 2009;4(7):e6325.
38. Padmanabhan N, et al. Mutation in folate metabolism causes epigenetic instability and transgenerational effects on development. Cell. 2013;155(1):81-93.
39. Pettenuzzo LF, et al. Ascorbic acid prevents water maze behavioral deficits caused by early postnatal methylmalonic acid administration in the rat. Brain Res. 2003;976(2):234-242.
40. Schirra HJ, et al. Altered metabolism of growth hormone receptor mutant mice: a combined NMR metabonomics and microarray study. PLoS One. 2008;3(7):e2764.
41. Sun Z, Lazar MA. Dissociating fatty liver and diabetes. Trends Endocrinol Metab. 2013;24(1):4-12.
42. Yadav VK, et al. Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med. 2010; 16(3):308-312.
43. Yadav VK, et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell. 2008;135(5):825-837.
44. Vanharanta M, Voutilainen S, Rissanen TH, Adlercreutz H, Salonen JT. Risk of cardiovascular disease-related and all-cause death according to serum concentrations of enterolactone: Kuopio Ischaemic Heart Disease Risk Factor Study. Arch Intern Med. 2003;163(9):1099-1104.
45. Stabler SP, Allen RH, Savage DG, Lindenbaum J. Clinical spectrum and diagnosis of cobalamin deficiency. Blood. 1990;76(5):871-881.